Side by side · Updated April 2026

Mounjaro vs. Mounjaro

Both are GLP-1 receptor agonists. Beyond that they differ in molecule, FDA indication, dose ceiling, and — most importantly to most people reading this — what the scale actually does over the long run.

Tirzepatide vs TirzepatideSame indication — Type 2 diabetes (with HFpEF and OSA indications added 2024)

Tirzepatide

Mounjaro

GIP + GLP-1 (dual agonist)

Made by: Eli Lilly
FDA approval: May 2022
Indication: Type 2 diabetes (with HFpEF and OSA indications added 2024)
Dose ceiling: 15 mg weekly
Typical loss: ~9–13% body weight at 1 year in T2D patients (SURPASS), ~22% off-label in non-diabetics at 15 mg
Cash list: $1,070–$1,180 list

Tirzepatide

Mounjaro

GIP + GLP-1 (dual agonist)

Made by: Eli Lilly
FDA approval: May 2022
Indication: Type 2 diabetes (with HFpEF and OSA indications added 2024)
Dose ceiling: 15 mg weekly
Typical loss: ~9–13% body weight at 1 year in T2D patients (SURPASS), ~22% off-label in non-diabetics at 15 mg
Cash list: $1,070–$1,180 list

The honest answer

Which one actually wins

Same molecule (tirzepatide). Branded Mounjaro is the FDA-manufactured pen or vial; compounded tirzepatide is from a 503A or 503B pharmacy. After the FDA declared the tirzepatide shortage resolved in August 2024, the legal pathway for compounded tirzepatide narrowed sharply — most reputable compounders wound down the product through late 2024.

Side by side